In the time it takes most newborns to sprout their first teeth, AveXis Inc. (NASDAQ: AVXS) looks ready to sink its teeth into the biotech industry. Since its market debut in early 2016, stellar clinical trial results for its lead candidate have propelled the stock about 349% higher.
A secondary share offering to bolster its cash balance has caused the company's market cap to rise even faster than its share price -- about 457% since its IPO, to about $2.25 billion. While the company's lead candidate has all the makings of a winner, investors are right to wonder if all the good news is already baked into the stock price, which is currently near its all-time high.
Source: Fool.com